Skip to main content

Chongqing Taiji Industry(Group) Co.,Ltd (600129.SS)

SHH Healthcare Drug Manufacturers - Specialty & GenericView data quality →
39.3Poor

ValueMarkers Composite Index

Top 4%#42,783 of 44,707

DCF data not available

Piotroski
6/9
Neutral
Beneish
-1.99
Investigate
Altman
1.17
Distress
DCF Value
-
N/A
ROIC
1.3%
Low
P/E
74.6
Growth
Updated: ·Source: Data sourced from SEC filings and institutional providers. Not financial advice.·Report data issue

Chongqing Taiji Industry(Group) Co.,Ltd (600129.SS) — VMCI valuation read

Chongqing Taiji Industry(Group) Co.,Ltd (600129.SS) carries a VMCI composite of 39/100, 11 points below the Healthcare sector median of 50. Among mid-cap names, that gap places 600129.SS in the bottom third on the five-pillar weighting (Value 35%, Quality 30%, Integrity 15%, Growth 12%, Risk 8%).

The 600129.SS insider tape has been silent for the past 30 days on Form 4. Where executives neither buy nor sell, the bull and bear cases lean harder on filings cadence and the next earnings line.

**Investor frame.** Value reads 600129.SS trades at 16.0x earnings, 11% below the Healthcare median of 18.0x, which compresses or extends through the 11.0x EV/EBITDA versus a Healthcare 12.0x. Quality: ROIC of 10.0% sits 0.0pp above the Healthcare median (10.0%). Risk: net debt to EBITDA of 2.7x is the rate-sensitivity line to watch, the line to track on Chongqing Taiji Industry(Group) Co.,Ltd's next 10-Q.

600129.SS rose 2.9% over the trailing 7 days, with a -23.8% read on a 30-day basis.

Chongqing Taiji Industry(Group) Co.,Ltd operates in the pharmaceutical industry in China and internationally. It researches, develops, produces, and sells Chinese medicine and health products. The company offers its products in various dosage forms, including tablets, oral liquids, syrups, dripping pills, granules, capsules, tinctures, powders, etc. It offers its products in various areas, such as digestive system, respiratory system, cardiovascular and cerebrovascular, pediatrics and gynecology, systemic anti-infective drugs, analgesia and antibiotics, orthopedics, cold clearing and cough relief, and endocrine and nervous system drugs. The company is based in Chongqing, China.

CEO: Zongbin Yu12,589 employeesCNwww.taiji.com

Top peers ranked by VM Score. Compare valuation, quality, and risk metrics across the sector.

Browse More

Key metrics explained

Definitions, formulas, and how ValueMarkers calculates each indicator used in 600129.SS’s VM Score.

Explore More

Compare Competitors

Weekly Stock Analysis - Free

5 undervalued stocks, fully modeled. Every Monday. No spam.

Cookie Preferences

We use cookies to analyze site usage and improve your experience. You can accept all, reject all, or customize your preferences.